Forgot Password?
Return to Course Listing

CME: Contemporary management strategies in the diagnosis and treatment of immune thrombocytopenia (ITP)


Activity Description / Statement of Need:

In this online, self-learning activity:

Immune thrombocytopenia (ITP) is a phenomenon characterized by a peripheral platelet count of less than 100 x 109/L in the absence of any discernable cause, with an increased risk of bleeding. Also known as thrombocytopenic purpura, it occurs in around two to four cases per 100,000 adults, with incidence peaking bimodally: Once between 20-30 years with female predominance and also at 60 years with even distribution between the sexes.

The diagnosis of ITP is one of exclusion and includes platelet autoantibody testing. However, it is complicated and associated with documented gaps in care, with preventable delays in diagnosis and misdiagnosis not uncommon. One study found that one in seven patients diagnosed with ITP were misdiagnosed and reclassified as they received additional clinical evaluation. Another study found that over 22% of patients with ITP did not receive guideline-recommended peripheral blood film examination. These diagnostic challenges have real-world consequences on patient lives, creating anxiety in 73% of patients who experience a delayed diagnosis.

Treatment goals include prevention of severe bleeding episodes, maintaining platelet counts for symptomatic patients, minimizing treatment toxicity, and maximizing health-related quality of life. Conventional therapy includes corticosteroids, intravenous immunoglobulin (IVIg), and anti-D IVIg. However, treatment challenges remain, including variability in practice between providers and high rates of relapse between following standard first-line therapies together with considerable patient frustration. Moreover, some patient subpopulations are more challenging to treat and are less likely to achieve therapeutic success.

Target Audience:

HCPs specializing in: hematology; physician assistants, nurse practitioners, nurses, pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with ITP.

Commercial Support Disclosure: This program is supported by an educational grant from Dova.

This activity is free of charge.


Release Date: April 09, 2022 -- Expiration Date: April 09, 2024

Faculty: Carlos Lopez, MD, MPH


Faculty introduction, disclosures

Review of ITP and ITP diagnosis

·       Epidemiology: Statistics and survival

·       Pathophysiology and clinical features

·       Burden of disease

  • Diagnosis and related challenges

·       Symptoms, bleeding severity, and prognosis

Pharmacotherapy for ITP

  • Goals of therapy
  • First-line therapy for newly diagnosed ITP: Platelet transfusion, corticosteroids, intravenous immunoglobulin (IVIg), and anti-D IVIg

·       Second line, later line, and investigational therapies

    • Thrombopoietin receptor agonists
    • Rituximab
    • Tyrosine kinase inhibition (Bruton’s, spleen)
    • Danazol
    • Other immunosuppressive approaches
    • Other hemostatic agents
    • Role of splenectomy
  • Role of combination therapy
  • Special patient populations
  • Challenges in care related to: Disease course, remission, and relapse
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • List challenges associated with the burden of disease, diagnosis, and treatment of patients with ITP
  • Recall guideline-recommended diagnostic practices and pharmacotherapy (first- and later-line) for ITP
  • Discuss investigational therapies for ITP, their mechanisms of action, and their anticipated place in therapy
  • Formulate a treatment plan for a patient with ITP


ACCME Activity #202281703


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure:

Carlos Lopez, MD, MPH, Hematology/Oncology Chief Fellow, Northwell Health, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Dova.


Copyright © 2021 by Scientia Perpetuam, LLC TM


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Atypical hemolytic uremic syndrome (aHUS): best practices and effective management

Paroxysmal nocturnal hemoglobinuria (PNH): Best practices and effective management

Transthyretin amyloidosis (ATTR): Prompt diagnosis, contemporary management strategies, and their impact on patient outcomes

Beta thalassemia: best practices and novel approaches in its recognition and treatment